每经AI快讯,2月11日,据礼来官微消息,礼来公司的安妥来利®和安妥来®(以上为两个剂型商品名,通用名均为:米吉珠单抗)获得国家药品监督管理局批准,用于治疗成人中重度活动性克罗恩病(Crohns Disease, CD)及成人中重度活动性溃疡性结肠炎(Ulcerative Colitis, UC)。安妥来利®(米吉珠单抗注射液(静脉输注))和安妥来®(米吉珠单抗注射液)是一种特异性靶向白介素-23...
Source Link每经AI快讯,2月11日,据礼来官微消息,礼来公司的安妥来利®和安妥来®(以上为两个剂型商品名,通用名均为:米吉珠单抗)获得国家药品监督管理局批准,用于治疗成人中重度活动性克罗恩病(Crohns Disease, CD)及成人中重度活动性溃疡性结肠炎(Ulcerative Colitis, UC)。安妥来利®(米吉珠单抗注射液(静脉输注))和安妥来®(米吉珠单抗注射液)是一种特异性靶向白介素-23...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.